CLINICAL AND IMMUNOLOGICAL RATIONALE FOR THE USE IN THERAPY IMMUNOMODULATOR GALAVIT® MIX-INFECTIONS OF THE GENITAL TRACT

Download full text PDF
Issue: 
1
Year: 
2015

Professor O. Gizinger, Biol. Dr.; Yu. Nefed'eva, Candidate of Medical Sciences

The article discusses the effects of the drug immunotropic Galavit® (Selba, Russia) in the treatment of viral and bacterial infections of the urogenital tract. Purpose – to assess the impact of the drug on Galavit® indicators of innate and adaptive immunity in the complex therapy of inflammatory diseases of the urogenital tract of women of reproductive age, the etiological agent of which are: herpes simplex virus type 2 and U. urealyticum и M. hominis. The results of the study showed that the introduction of the drug to patients in a comprehensive scheme Galavit® therapy at an initial dose 100 mg daily (5 injections); followed by 100 mg every other day (5 injections); At the end of the course-10 rectal suppository 1 time in 3 days promotes normalization factors antimicrobial protection and resolution of clinical symptoms.

Keywords: 
Galavit®
complex therapy
innate immunity
adaptive immunity



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Gizinger O.A., Letjaeva O.I. Immunomoduljatory v ginekologii: k voprosu o kliniko-mikrobiologicheskoj effektivnosti i immunomoduli-rujuschej terapii v kompleksnom lechenii mikoplazmennoj infektsii uroge-nital'nogo trakta u zhenschin reproduktivnogo vozrasta // Vrach. – 2014; 3: 46–9.
  2. Gizinger O.A., Letjaeva O.I. Immunomoduljatory v kompleksnom lechenii 2. mikoplazmennoj infektsii urogenital'nogo trakta u zhenschin reproduktiv-nogo vozrasta // Vrach. – 2014; 2: 62–7.
  3. Gizinger O.A., Dolgushin I.I., Letjaeva O.I. Faktory mestnogo immuniteta reproduktivnoj sistemy u zhenschin s hlamidijnoj infektsiej // Zhurn. mikrobiol., epidemiol. i immunobiol. – 2005; 4: 65–9
  4. Gizinger O.A., Letjaeva O.I., Plehanova E.V. i dr. Immunoterapija v korrektsii disfunktsij faktorov vrozhdennogo i adaptativnogo immuniteta pri oslozhnennoj urogenital'noj infektsii // Ros. immunol. zhurn. – 2013; 7 (2–3): 272–3.
  5. D'jakonova V.A., Pak V.G., Budihina A.S. Otsenka funktsional'noj aktivnosti fagotsitarnoj sistemy cheloveka v norme i pri patologii / M., 2008; 123 s.
  6. Ivanov A.A., Gladkih O.P., Kuznetsova A.V. i dr. Mezhkletochnye i kletochno-matriksnye vzaimodejstvija v patologii // Molekuljarnaja meditsi-na. – 2005; 2: 16–21.
  7. Kubanova A.A., Rahmatullina M.R. Urogenital'nye infektsionnye zabolevanija, vyzvannye genital'nymi mikoplazmami: klinich. rekomenda-tsii // Vestn. dermatol. i venerol.– 2009; 3: 65–72.
  8. Letjaeva O.I., Gizinger O.A., Ziganshin O.R. Genital'nyj gerpes: dolgo srochnye podhody k terapii pozhiznennoj infektsii // Klin. dermatol. i venerol. – 2013; 6: 61–4.
  9. Rjabicheva T.G., Varaksin N.A., Timofeeva N.V. i dr. Opredelenie tsito kinov metodom immunofermentnogo analiza // Inform. bjul. «Novosti Vektor-Best». – 2004; 4 (34).
  10. Serov V.N., Tverdikova M.A., Veresova A.A. Immunomoduljatory v kompleksnoj terapii vospalitel'nyh zabolevanij organov malogo taza // RMZh. – 2011; 20: 1218–23.
  11. Shul'zhenko A.E., Zujkova I.N. Galavit v terapii hronicheskoj retsidi-virujuschej gerpesvirusnoj infektsii // Novye lekarstva. – 2003; 3: 23–7.
  12. Haitov R.M., Jarilin A.A., Pinegin B.V. Rukovodstvo po klinicheskoj immunologii. Diagnostika zabolevanij immunnoj sistemy / M., 2009; 352 s.
  13. Haldin A.A., L'vov A.N., Markova Ju.A. i dr. Standartizatsija vedenija . patsientov s retsidivirujuschim prostym gerpesom: terapija, profilaktika i konsul'tirovanie // Sovrem. problemy dermatovenerol., immunol. i vracheb-noj kosmetol. – 2010; 2: 59–65.
  14. Viscardi R., Hasday J. Role of Ureaplasma species in neonatal chronic lung 14. disease: epidemiologic and experimental evidence // Pediatr. Res. – 2009; 65 (5): 84–90.
  15. Kar M., Sengupta J., Bhargava V. Immunohistochemical localization of macrophage CD68+, HLA–DR+, L1+ and CD44+ subsets in uterine endometrium during different phases of menstrual cycle // J. Physiol. Pharmacol. – 2004; 48 (3): 293–303.